Home Life Sciences Allergic Rhinitis pipeline Direct Report Coverage 2017

Allergic Rhinitis pipeline Direct Report Coverage 2017


Allergic RhinitisAllergic Rhinitis Pipeline and Therapeutics Development H1 2017 provides comprehensive information on the therapeutics under development for Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Allergic Rhinitis pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision-making capabilities and helps to create effective counter-strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Sample copy is available at


Companies Involved in Allergic Rhinitis Development are AFFiRiS AG, ALK-Abello A/S, AlleCures Inc, Allergy Therapeutics Plc, ASIT Biotech SA, Axikin Pharmaceuticals Inc, Chong Kun Dang Pharmaceutical Corp, Chrysalis BioTherapeutics Inc, Fountain Biopharma Inc, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd etc.

Drug Profiles discussed in this research are Allergen for Allergic Rhinitis, Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis, Allergen for Seasonal Grass Pollen-Induced Allergic Rhinitis and Rhino-Conjunctivitis etc.

The Allergic Rhinitis pipeline guide also reviews of key players involved in therapeutic development for Allergic Rhinitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 5 and 1 respectively.

Report at


Scope of this report:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Allergic Rhinitis. The pipeline guide reviews pipeline therapeutics for Allergic Rhinitis by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Allergic Rhinitis therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Allergic Rhinitis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Allergic Rhinitis.
  • This research report can: Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Allergic Rhinitis. Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Allergic Rhinitis pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Please enter your comment!
Please enter your name here